Monday, October 10, 2022 8:55:08 PM
Flipper, post 519498:
In the Optune trial, in the treatment arm, only 16 of 466 (3.4%) were alive, beating hearts, at five years (from time zero). In the Stupp protocol arm, according to recent reports, 0 out of 229 were alive, beating hearts, at five years, but according to Stupp back then, 2 out of 229 were alive at five years, beating hearts. (Time = two years from last randomized patient’s entry into the trial)
At just two years after the last patient was randomized into the Optune arm. only 57 (including 16 above) (12%) out of 466 patients were still alive somewhere at two or more years from randomization. The likelihood is five year survival, beating hearts, was under 5% (from time zero) at five years had they followed the trial further to five years from last randomization.. Which they did not. At the same time as they stopped the trial two years after last patient was enrolled, only 16 of 229 (7%) patients were still alive. The likelihood is less than 2% (Stupp protocol) might live until five years (from time zero) had the trial been followed until five years from last patient’s randomization into trial. Imo.
Optune shamelessly exaggerates their five year survival, and they demonstrate how research without follow up can make a mockery of the KM curve.
All estimates reflect survival from time zero.
The Optune trial was never ever blinded for survival.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
